http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020168741-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a6f422b091ba12ea61d4adbf1b0e8e |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7042 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-381 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-381 |
| filingDate | 2019-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_515362ee2065e4eaade6d729b46bd70f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c40b2b72ab23a121c415b5d321d20cff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_298eba204e3d7f4f05fd80fe43423cb8 |
| publicationDate | 2020-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020168741-A1 |
| titleOfInvention | Use of canagliflozin in preparation of anti-tumor medication |
| abstract | Provided is a use of canagliflozin in preparation of an anti-tumor medication, in particular, a use in the preparation of a medication for treating solid tumors. Research shows that canagliflozin has remarkable downregulating effect on the immune checkpoint protein, PD-L1, in many types of tumor cells, and, in a model of T-cell and tumor cell co-incubation, effectively enhances the killing effect of T-cell on tumor cells, thereby expanding the clinical use of the chemical medication, canagliflozin, in tumor immunotherapy. The present invention provides a new medical use of canagliflozin and provides new approaches and potential targets for PD-L1 small molecule medication-based research and development. |
| priorityDate | 2019-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 70.